Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 4, Issue 120, Pages 120ps2-120ps2
Publisher
American Association for the Advancement of Science (AAAS)
Online
2012-02-09
DOI
10.1126/scitranslmed.3003728
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
- (2011) C. M. Lovly et al. CANCER RESEARCH
- Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
- (2011) A. K. Murugan et al. CANCER RESEARCH
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- Crizotinib in Anaplastic Large-Cell Lymphoma
- (2011) Carlo Gambacorti-Passerini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
- (2011) S. C. Bresler et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers
- (2010) T. Sasaki et al. CANCER RESEARCH
- Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer
- (2010) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
- (2009) E. Lin et al. MOLECULAR CANCER RESEARCH
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
- Inflammatory myofibroblastic tumours: where are we now?
- (2007) B C Gleason et al. JOURNAL OF CLINICAL PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now